Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10087)
◆英語タイトル:Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10087
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases associated with reduced muscle performance. The company’s pipeline encompasses omecamtiv mecarbil, a novel cardiac myosin activator in Phase 3 for heart failure; and reldesemtiv, a next-generation fast skeletal muscle troponin activator in Phase 2 for the treatment of spinal muscular atrophy; chronic obstructive pulmonary disease; and in Phase 1b for frailty. It is also investigating reldesemtiv for amyotrophic lateral sclerosis. It has licensing agreements with Amgen and Astellas for advancing its drug candidates. Cytokinetics is headquartered in South San Francisco, California, the US.

Cytokinetics Inc (CYTK) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Equity Offering 15
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc – Key Competitors 26
Cytokinetics Inc – Key Employees 27
Cytokinetics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Nov 01, 2018: Cytokinetics reports third quarter 2018 financial results 29
Jul 26, 2018: Cytokinetics Reports Second Quarter 2018 Financial Results 31
Apr 26, 2018: Cytokinetics Reports First Quarter 2018 Financial Results 34
Feb 15, 2018: Cytokinetics Reports Fourth Quarter 2017 Financial Results 36
Oct 26, 2017: Cytokinetics Reports Third Quarter 2017 Financial Results 38
Aug 02, 2017: Cytokinetics Reports Second Quarter 2017 Financial Results 40
Apr 27, 2017: Cytokinetics Reports First Quarter 2017 Financial Results 42
Feb 16, 2017: Cytokinetics Reports Fourth Quarter 2016 Financial Results 44
Corporate Communications 47
Feb 12, 2018: Cytokinetics Appoints Robert Califf, M.D., to Board of Directors 47
Product News 48
Nov 30, 2017: New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS 48
Product Approvals 49
May 15, 2017: Cytokinetics Announces Orphan Drug Designation for CK-2127107 for the Treatment of Spinal Muscular Atrophy 49
Clinical Trials 50
Apr 24, 2018: Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference 50
Feb 21, 2018: Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 51
Jan 03, 2018: Cytokinetics Provides on CK-2127107 52
Dec 11, 2017: Cytokinetics Publishes Clinical Trial Data for CK-2127107 53
Nov 30, 2017: New Publication Summarizes Phase 1 Studies Of CK-2127107 Showing Tolerability And Amplification Of Skeletal Muscle Response To Nerve Activation 54
Jul 27, 2017: Cytokinetics Announces Start of FORTITUDE-ALS, a Phase 2 Clinical Trial of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis 56
Jul 05, 2017: Cytokinetics Announces Baseline Data From First Cohort of Phase 2 Clinical Trial of CK-2127107 in Patients With SMA 57
Mar 29, 2017: Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients With Spinal Muscular Atrophy 59
Mar 22, 2017: Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Cytokinetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cytokinetics Enters Into Licensing Agreement With Astellas Pharma For CK-2127107 11
Astellas Pharma Expands Licensing Agreement with Cytokinetics 13
Cytokinetics Plans to Raise Funds through Public Offering of Securities 15
Cytokinetics Prices Public Offering of Shares for USD75 Million 16
Cytokinetics to Raise up to USD40 Million in Public Offering of Shares 17
Cytokinetics Raises USD10 Million in Private Placement of Shares 18
Cytokinetics Completes Public Offering Of Shares For US$40.3 Million 19
Cytokinetics Completes Public Offering Of Shares For US$5 Million 21
Cytokinetics Completes Public Offering Of Common Stock And Warrants For US$42.5 Million 22
Cytokinetics Completes Public Offering Of Preferred Stock And Warrants For US$17.5 Million 24
Cytokinetics Inc, Key Competitors 26
Cytokinetics Inc, Key Employees 27

List of Figures
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytokinetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Cytokinetics Inc (CYTK):製薬・医療:M&Aディール及び事業提携情報(Cytokinetics Inc (CYTK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆